The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, discusses changes in genomic prognostic markers in chronic lymphocytic leukemia (CLL), highlighting that TP53 abnormalities and the immunoglobulin locus remain important, particularly for identifying high-risk CLL and guiding treatment decisions. Dr Schuh notes that while mutated CLL responds well to single-agent fixed-duration therapy, unmutated patients may require more careful consideration of MRD-directed therapy, and that complex karyotype and stereotyped subsets are also important to consider. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
